|
Are
Drugmakers Becoming More Vulnerable to Losing Patents?
March
11, 2008--The
Financial Times notes
that US courts have become more skeptical of existing patents,
making it harder to stop generic manufacturers from launching
competing drugs. Last year, an important appeals court made it
easier to challenge drug patents on the grounds that their
chemical formulas are obvious. Case in point: A US court recently
invalidated Bayer’s patent for its Yasmin (drospirenone
and ethinyl estradiol) oral
contraceptive on grounds of obviousness. Financial
Times
|
